International Journal of Cancer Management

Published by: Kowsar

Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs)

Hamed Hajipour 1 , Hamed Hamishehkar 2 , Mohammad Rahmati-yamchi 3 , Dariush Shanehbandi 4 , Saeed Nazari Soltan Ahmad 1 and Akbar Hasani 2 , *
Authors Information
1 Student Research Committee and Department of Biochemistry and Clinical Laboratories, Faculty of Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • International Journal of Cancer Management: January 2018, 11 (1); e9402
  • Published Online: January 31, 2018
  • Article Type: Research Article
  • Received: October 18, 2016
  • Revised: February 20, 2017
  • Accepted: January 24, 2018
  • DOI: 10.5812/ijcm.9402

To Cite: Hajipour H, Hamishehkar H, Rahmati-yamchi M, Shanehbandi D, Nazari Soltan Ahmad S, et al. Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs), Int J Cancer Manag. 2018 ; 11(1):e9402. doi: 10.5812/ijcm.9402.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 2. Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett. 2014;342(2):248-56. doi: 10.1016/j.canlet.2012.02.011. [PubMed: 22391123].
  • 3. Häkkinen SH, Kärenlampi SO, Mykkänen HM, Heinonen IM, Törrönen AR. Ellagic acid content in berries: Influence of domestic processing and storage. Europ Food Res Technol. 2000;212(1):75-80. doi: 10.1007/s002170000184.
  • 4. Vanella L, Barbagallo I, Acquaviva R, Di Giacomo C, Cardile V, Abraham NG, et al. Ellagic acid: cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines. Curr Pharm Des. 2013;19(15):2728-36. [PubMed: 23092326].
  • 5. Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Li Volti G, Cardile V, et al. Effects of ellagic Acid on angiogenic factors in prostate cancer cells. Cancers (Basel). 2013;5(2):726-38. doi: 10.3390/cancers5020726. [PubMed: 24216999].
  • 6. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC, et al. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005;25(2A):971-9. [PubMed: 15868936].
  • 7. Larrosa M, Tomas-Barberan FA, Espin JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 2006;17(9):611-25. doi: 10.1016/j.jnutbio.2005.09.004. [PubMed: 16426830].
  • 8. Losso JN, Bansode RR, Trappey A2, Bawadi HA, Truax R. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem. 2004;15(11):672-8. doi: 10.1016/j.jnutbio.2004.06.004. [PubMed: 15590271].
  • 9. Bala I, Bhardwaj V, Hariharan S, Kumar MN. Analytical methods for assay of ellagic acid and its solubility studies. J Pharm Biomed Anal. 2006;40(1):206-10. doi: 10.1016/j.jpba.2005.07.006. [PubMed: 16111850].
  • 10. Murugan V, Mukherjee K, Maiti K, Mukherjee PK. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J Agric Food Chem. 2009;57(11):4559-65. doi: 10.1021/jf8037105. [PubMed: 19449806].
  • 11. Pandey R, Ahmad Z, Sharma S, Khuller GK. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm. 2005;301(1-2):268-76. doi: 10.1016/j.ijpharm.2005.05.027. [PubMed: 16023808].
  • 12. Kakran M, Sahoo NG, Li L. Dissolution enhancement of quercetin through nanofabrication, complexation, and solid dispersion. Colloids Surf B Biointerfaces. 2011;88(1):121-30. doi: 10.1016/j.colsurfb.2011.06.020. [PubMed: 21764266].
  • 13. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77. [PubMed: 10840199].
  • 14. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1-2):132-8. doi: 10.1016/j.ijpharm.2008.06.028. [PubMed: 18657601].
  • 15. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): Method, characterization and applications. Int Current Pharmaceutical J. 2012;1(11):384-93.
  • 16. Danhier F, Danhier P, De Saedeleer CJ, Fruytier AC, Schleich N, des Rieux A, et al. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm. 2015;479(2):399-407. doi: 10.1016/j.ijpharm.2015.01.009. [PubMed: 25578367].
  • 17. Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, et al. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Adv Funct Mater. 2015;25(18):2646-59. doi: 10.1002/adfm.201404629. [PubMed: 26097445].
  • 18. Amiji MM. Nanotechnology for cancer therapy. CRC press; 2006.
  • 19. Liu Y, Jie X, Guo Y, Zhang X, Wang J, Xue C. Green Synthesis of Oxovanadium(IV)/chitosan Nanocomposites and Its Ameliorative Effect on Hyperglycemia, Insulin Resistance, and Oxidative Stress. Biol Trace Elem Res. 2016;169(2):310-9. doi: 10.1007/s12011-015-0420-6. [PubMed: 26144273].
  • 20. Kathe N, Henriksen B, Chauhan H. Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations. Drug Dev Ind Pharm. 2014;40(12):1565-75. doi: 10.3109/03639045.2014.909840. [PubMed: 24766553].
  • 21. Li B, Harich K, Wegiel L, Taylor LS, Edgar KJ. Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions. Carbohydr Polym. 2013;92(2):1443-50. doi: 10.1016/j.carbpol.2012.10.051. [PubMed: 23399175].
  • 22. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MN. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm Res. 2007;24(5):899-908. doi: 10.1007/s11095-006-9207-y. [PubMed: 17377747].
  • 23. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2014;117:21-8. doi: 10.1016/j.colsurfb.2014.01.055. [PubMed: 24607519].
  • 24. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1-2):216-27. doi: 10.1016/j.ijpharm.2012.03.032. [PubMed: 22465548].
  • 25. Hamishehkar H, Shokri J, Fallahi S, Jahangiri A, Ghanbarzadeh S, Kouhsoltani M. Histopathological evaluation of caffeine-loaded solid lipid nanoparticles in efficient treatment of cellulite. Drug Dev Ind Pharm. 2015;41(10):1640-6. doi: 10.3109/03639045.2014.980426. [PubMed: 25382163].
  • 26. Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces. 2013;110:313-20. doi: 10.1016/j.colsurfb.2013.03.039. [PubMed: 23732810].
  • 27. Eskandani M, Nazemiyeh H. Self-reporter shikonin-Act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation. Eur J Pharm Sci. 2014;59:49-57. doi: 10.1016/j.ejps.2014.04.009. [PubMed: 24768857].
  • 28. Wang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, et al. Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions. Colloids Surf B Biointerfaces. 2012;98:105-11. doi: 10.1016/j.colsurfb.2012.05.006. [PubMed: 22659379].
  • 29. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421. doi: 10.1016/j.bcp.2006.02.009. [PubMed: 16563357].
  • 30. Malik A, Afaq S, Shahid M, Akhtar K, Assiri A. Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. Asian Pac J Trop Med. 2011;4(7):550-5. doi: 10.1016/S1995-7645(11)60144-2. [PubMed: 21803307].
  • 31. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644(2-3):229-49. doi: 10.1016/j.bbamcr.2003.08.009. [PubMed: 14996506].
  • 32. Mbazima VG, Mokgotho MP, February F, Rees DJG, Mampuru L. Alteration of Bax-to-Bcl-2 ratio modulates the anticancer activity of methanolic extract of Commelina benghalensis (Commelinaceae) in Jurkat T cells. African J Biotechnol. 2008;7(20).
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments